CGEN - Rasio utang marang kapitalisasi buku Compugen Ltd

Despite Middle East instability, Compugen Ltd. (CGEN) has moved its clinical trials to the US, where the indicator stands at 0.03. This price chart reflects the development of a business that minimizes environmental impact through digital modeling. Compugen Ltd. (CGEN) relies on highly qualified bioinformaticians, attracting industry elite with modern software and generous stock options to identify new oncological targets.

This ratio determines the company's degree of dependence on debt capital relative to its equity, reflecting the balance between financial stability and expansion rates. By analyzing the historical debt-to-book capitalization ratio, an investor sees the ratio of liabilities to asset value, which is critical for Compugen Ltd. (CGEN) when financing complex biomaterial logistics and establishing high-tech supply chains for immuno-oncology drugs.